Related Experiment Video
Updated: Jun 15, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Predictive clinical indicators of refractory Mycoplasma pneumoniae pneumonia in children: A retrospective cohort
1Department of Pharmacy, Hejiang People's Hospital, Luzhou City, Sichuan Province, China.
Insights
Identifying key clinical indicators like higher BMI and elevated inflammatory markers can predict refractory Mycoplasma pneumoniae pneumonia (RMPP) in children. A developed model aids early RMPP detection and management for improved outcomes.
Area of Science:
- Pediatric Infectious Diseases
- Respiratory Medicine
- Clinical Diagnostics
Background:
- Mycoplasma pneumoniae pneumonia (MPP) is common in children, but refractory cases (RMPP) require specific management strategies.
- Early identification of RMPP is crucial for timely intervention and preventing severe outcomes.
- Existing predictive tools for RMPP in pediatric populations are limited.
Purpose of the Study:
- To identify clinical indicators that predict refractory Mycoplasma pneumoniae pneumonia (RMPP) in children.
- To develop and validate a predictive model for early RMPP identification.
- To improve clinical management of pediatric RMPP through timely intervention.
Main Methods:
- Retrospective cohort study of 338 children with RMPP out of 1500 MPP cases.
- Analysis of clinical, demographic, and laboratory data including BMI, fever duration, WBC, CRP, NLR, and PLR.
- Univariate and multivariate logistic regression for predictor identification and model development.
Main Results:
- Higher body mass index, longer fever duration, elevated white blood cell count, neutrophil count, and C-reactive protein were significant predictors.
- Increased neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) also predicted RMPP.
- The developed predictive model showed excellent diagnostic performance (AUC = 0.963).
Conclusions:
- Key clinical indicators accurately predict RMPP in children.
- The established predictive model serves as a valuable tool for early RMPP diagnosis.
- Timely intervention based on predictive modeling can potentially improve RMPP outcomes.
Abstract:
To determine the clinical indicators predictive of refractory Mycoplasma pneumoniae pneumonia (RMPP) in children and develop a robust predictive model to aid in early identification and management. A retrospective cohort study was conducted on 338 children diagnosed with RMPP out of a total of 1500 cases of Mycoplasma pneumoniae at a single tertiary hospital from May 2021 to November 2023. Clinical and demographic data analyzed included age, gender, parents' educational level, household income, body mass index, allergic constitution, and laboratory findings such as white blood cell count, neutrophil and lymphocyte counts, platelet count, and levels of C-reactive protein (CRP), D-dimer, and procalcitonin. Univariate and multivariate logistic regression analyses were performed to identify significant predictors of RMPP, and a predictive model was developed. Among the RMPP cohort, 52.4% were female, with a mean age of 6.07 ± 2.78 years. Multivariate analysis identified several significant predictors of poor prognosis, including higher body mass index, longer duration of fever, elevated white blood cell count, neutrophil count, C-reactive protein levels, and increased neutrophil to lymphocyte ratio and platelet to lymphocyte ratio. The model demonstrated outstanding diagnostic performance, with an area under the receiver operating characteristic curve of 0.963 (95% confidence interval: 0.946-0.981). Our study identifies key clinical indicators with significant diagnostic accuracy for predicting RMPP in children. The predictive model established offers a valuable tool for clinicians, potentially improving RMPP outcomes through timely intervention.
More Related Videos
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...